Company Overview
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
Why Investors Should Care
Trades at a P/E of 0.0, below the sector median of 24.8.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -96.98% |
| 6 Months: | -69.45% |
| 3 Months: | -57.92% |
| 1 Month: | -33.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)26.91 · Oversold
P/E of 0.02 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DCOY Decoy Therapeutics Inc. PHARMA | 2.63 | 0.02 | $1.72M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 242.55K | 335.52K | 413.60K | 282.83K | 178.58K | 245.50K | 469.05K | 163.07K | 104.98K | 895.78K | 874.95K | 1.13M | 1.24M | 1.38M | 1.27M | 571.39K | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | - | - | -8.17M | - | -9.70M | -11.47M | -10.74M | -7.98M | -8.35M | -8.88M | -9.41M | -8.09M | -8.28M | -9.10M | -313.51K | -2.02M | -2.24M | -912.10K | -3.76M | -2.37M | -1.90M | -1.76M | -1.80M | -3.12M | -3.75M | -6.12M | -4.76M | -14.49M | -5.42M | -3.97M | -2.53M | -1.77M | -1.47M | -1.01M | -1.72M | -965.57K | -895.13K | -2.28M |
| Net Income | -1.99M | -3.74M | -6.02M | -7.08M | -8.15M | -7.89M | -9.59M | -11.36M | -10.64M | -7.90M | -8.27M | -8.80M | -9.33M | -8.03M | -381.55K | 111.23K | -307.45K | -2.01M | -1.52M | -903.64K | -2.63M | -2.08M | -1.78M | -1.72M | -1.85M | -3.07M | -3.74M | -6.11M | -4.72M | -14.41M | -5.34M | -3.88M | -2.44M | -1.72M | -1.42M | -972.12K | -1.71M | -957.83K | -873.47K | -2.22M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.13 | -0.10 | -0.06 | -0.07 | -2.09 | -3.30 | -2.20 | -6.41 | -2.23 | -11.45 | -5.21 | -3.27 | -2.37 | -11.38 | -240.07 | -0.45 | -1.81 | -4.18 |
| R&D Expense | 909.12K | 1.97M | 2.80M | 3.19M | 3.45M | 3.31M | 4.39M | 6.09M | 5.67M | 4.23M | 3.91M | 4.08M | 4.74M | 4.26M | 4.68M | 6.17M | 353.61K | 187.76K | 1.71K | 840.14K | 1.14M | 1.64M | 1.44M | 1.80M | 1.74M | 2.10M | 2.02M | 4.44M | 2.92M | 3.79M | 3.73M | 2.35M | 1.04M | 243.00K | 214.45K | 137.23K | 75.53K | 116.38K | 61.83K | 749.81K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.01M | 1.27M | 1.95M | 3.47M | 5.23M | 1.84M | 0 | - | - | - |
| Operating Income | -8.03M | -29.21M | -39.89M | -34.73M | -1.68M | -8.27M | -7.79M | -12.81M | -31.84M | -12.89M | -5.73M | -12.61M |
| Net Income | -8.01M | -29.14M | -39.49M | -34.43M | -1.67M | -6.94M | -7.35M | -12.77M | -31.61M | -12.54M | -5.58M | -12.52M |
| Diluted EPS | - | - | - | - | - | - | -0.50 | -7.72 | -14.88 | -30.74 | -69.54 | -129.10 |
| R&D Expense | 4.00M | 12.75M | 20.38M | 16.99M | 1.29M | 4.02M | 6.91M | 8.55M | 15.84M | 7.17M | 770.03K | 368.17K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Feb 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 35.61M | 95.07M | 63.21M | 34.99M | 6.61M | 13.89M | 24.93M | 40.83M | 14.65M | 6.59M | 3.02M | 11.06M |
| Total Equity | 0 | -6.54M | 92.19M | 59.32M | -2.90M | -1.27M | 10.58M | 22.16M | 38.72M | 10.38M | 5.29M | 1.51M | 5.89M |
| Cash & Equivalents | - | - | - | - | 19.19M | 3.23M | 3.74M | 11.12M | 29.21M | 12.11M | 5.90M | 2.43M | 10.71M |
| Total Liabilities | - | 1.12M | 2.88M | 3.90M | 5.89M | 7.88M | 3.31M | 2.77M | 2.11M | 4.27M | 1.30M | 1.51M | 5.17M |
| Current Liabilities | - | 1.07M | 2.85M | 3.89M | 5.85M | 1.11M | - | - | - | - | - | 1.51M | 5.17M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.48M | -20.75M | -32.05M | -27.72M | 4.18M | -11.58M | -10.31M | -10.20M | -17.60M | -12.85M | -4.53M | -4.83M |
| Investing Cash Flow | -76.14K | -27.27M | -12.24M | 24.49M | 0 | 5.61M | -2.60K | 0 | -1.50M | 0 | 0 | 764.74K |
| Financing Cash Flow | 40.41M | 80.84M | 22.10K | 2.63K | 1.44M | 3.58M | 17.69M | 28.30M | 1.99M | 6.64M | 1.06M | 12.34M |
| Capital Expenditure | -76.14K | -265.62K | -559.38K | -113.50K | -0 | -0 | -2.60K | -0 | - | - | - | - |
| Free Cash Flow | -6.56M | -21.01M | -32.61M | -27.84M | 4.18M | -11.58M | -10.31M | -10.20M | - | - | - | - |
| Dividends Paid | - | - | - | - | 0 | 133.59K | 0 | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -3,946.5% | -2,724.6% | -86.3% | -238.5% | -148.8% | -696.3% | - | - | - | - |
| Net Margin % | - | - | -3,907.6% | -2,701.7% | -85.6% | -200.2% | -140.5% | -693.8% | - | - | - | - |
| ROE % | 122.5% | -31.6% | -66.6% | 1,187.2% | 131.4% | -65.6% | -33.2% | -33.0% | -304.4% | -237.2% | -368.8% | -212.6% |
| ROCE % | -23.2% | -31.7% | -67.2% | -119.1% | -30.6% | - | - | - | - | - | -379.3% | -214.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 0.62% | 4.03K | $11.21K |
| 2 | Tower Research Capital LLC (TRC) | 0.04% | 256 | $711 |
| 3 | Caitong International Asset Management Co., Ltd | - | 2 | $5 |
| 4 | UBS Group AG | - | 25 | $69 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DCOY
Decoy is designing one antiviral for many viruses. Its CEO speaks Sept. 10. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNb2dEY2Qtd1FjV2xHZkFFVWh6SjUzTnNiNk5TcF9wNXhybW9oc0gwMVVBQUJ4d0oxVWZLOFFTVnRGamtKRFllY3U1Q3k0N2FuSm9Cck0tbUZfWHFmZEZrY1IwLUd1N1RDdEJ6c18zeEVLeGdtNmQ0ZGkycEhvaEtZWmtBbDNIZXBNTUVwbz…
DCOY Stock Nearly Doubled In Value Today – What’s Driving This Mega Rally? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOZ3pBWFZPbmNVbGlNd3FyeFhnUFprVnNWa1d1VXpBS3dUc0pubUtucWd1aFNqY0kzeERLc0liME1tbkhRY2FOR2w1M3ZZUjR5SFhSbE5qNDBQWktFU3J6VExoaTE0dUhscS1iR19JUzFDeXhGd1oyTzlKa3JnSTIwajFtS1BaWEgza0RwVH…
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing - PR Newswire
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPUjFHb2M0QkZaMENTMGRpS0d5OGtaRlk1SXZoOVZhOVBvdHV0RnQ4OEpHeFd5NnZyV0ljWEtnSV96UlQ1UUxZWkpoUWxUUzJZb2VXb2FDZHFrMkQxaThTbjZmQkY3WHZ0eGkyb2h5SWpLQ2JzTkZBZEJtM0w2dnJFMVdyWFpSWWtHSUtCb2…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBTT2c5SWFjLVdnd3NfbWdFdUZaSGQtRFh5YWdNbjNfbE9YYWgwY3VUM3pjLUNWQUZTRnQ4NjZQazBSVDRfeFlNZ3JoLXhabzdq?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Decoy Therapeutics (DCOY) CFO granted multi-year stock award - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQc29kangwblZUVWkzMUI5MzY0MjFZVzNIdWtvVGVrekVmUnVhUWtvYmxTOWVjUmZWZkZpdzVyWERSQ0xyTm4zTFVnTjZJLVRSVUhyQ0EzekF0c21WQWVmWU1ISVNmcm9sZDZ0dkVMc3pFYUFCTkwzdldJSlN5VUVaeUdtNkZhQ0ZNY3gzN1…
DCOY - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1rU2VrVDRydDRNYnhhVFZVX3RRU0Vyb09UTUpGQTRzZ1JvdU9vMi1DLVJsZnJQMmg3UklLRm0wWi1Hd0JVa3c?oc=5" target="_blank">DCOY</a> <font color="#6f6f6f">Finviz</font>…
DCOY — Frequently Asked Questions
What is the current share price of Decoy Therapeutics Inc. (DCOY)?
As of 2026-09-19 21:16 PDT, Decoy Therapeutics Inc. (DCOY) trades at $2.63 on NasdaqCM. Its 52-week range is $2.63 to $87.12.
What is the market capitalisation of DCOY?
Decoy Therapeutics Inc. (DCOY) has a market capitalisation of $1.72M on NasdaqCM.
What is the P/E ratio of DCOY?
DCOY trades at a trailing price-to-earnings (P/E) ratio of 0.02. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.34.
Is DCOY a good stock to buy?
This page provides a data-driven analysis of Decoy Therapeutics Inc. (DCOY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.